IMCR Stock Immunocore Holdings (IMCR, $42.74) RSI Indicator left the oversold zone on June 03, 2024
IMCR's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for IMCR turned positive on November 06, 2024. Looking at past instances where IMCR's MACD turned positive, the stock continued to rise in of 32 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2024. You may want to consider a long position or call options on IMCR as a result. In of 51 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
IMCR moved above its 50-day moving average on November 05, 2024 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for IMCR crossed bullishly above the 50-day moving average on November 08, 2024. This indicates that the trend has shifted higher and could be considered a buy signal. In of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IMCR advanced for three days, in of 218 cases, the price rose further within the following month. The odds of a continued upward trend are .
IMCR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 161 cases where IMCR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for IMCR moved out of overbought territory on October 21, 2024. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 39 cases where IMCR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMCR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.320) is normal, around the industry mean (14.655). P/E Ratio (0.000) is within average values for comparable stocks, (96.848). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.824). IMCR has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (5.488) is also within normal values, averaging (218.428).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. IMCR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
General Information
Industry Biotechnology